Status: Not yet recruiting
A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer
This is a Phase II, multicenter, single-arm dose expansion trial planned to enroll up to 30 subjects with advanced or metastatic ovarian cancer. The Objective is to conduct a preliminary evaluation of the efficacy, the safety, tolerability and PK profile of DAT-2645
Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Danatlas Pharmaceuticals Co., LtdUpdated: Jun 25, 2026Locations: 2
Eligibility criteria
sign a written informed consent form [+9]
Received small-molecule chemotherapy or targeted therapy within 2 weeks or 5 hal... [+8]